Table 3.
Unadjusted and adjusted linear regression analysis with TBRmax as the dependent variable
| Characteristic | Unadjusted analyses | Adjusted analysesα | ||
|---|---|---|---|---|
| B (95 % CI) | p value | B (95 % CI) | p value | |
| ESR | 0.009(−0.029-0.048) | 0.602 | 0.024(−0.021-0.070) | 0.256 |
| CRP | −0.056(−0.272-0.159) | 0.584 | −0.075(−0.318-0.168) | 0.513 |
| DAS28 | 0.060(−0.623-0.744) | 0.850 | 0.087(−0.638-0.910) | 0.831 |
| Disease duration | 0.023(−0.003-0.050) | 0.084 | 0.038(0.002-0.074) | 0.040 |
| Disease duration until start of TNF inhibition | 0.064(0.015-0.113) | 0.015 | 0.081(0.004-0.158) | 0.040 |
Data are unadjusted coefficient (B) with 95 % confidence intervals (CI)
TBR max maximum target-to-background ratio, ESR erythrocyte sedimentation rate, CRP C-reactive protein, DAS28 disease activity score based on 28 joints
αAdjusted for BMI, systolic blood pressure and current smoking